Robert W. Azelby
Robert W. Azelby, Former President and CEO of Eliem Therapeutics, Inc.
- President and CEO of Eliem Therapeutics, Inc., a biotechnology company focused on neuronal excitability disorders, from 2020 until 2023
- President and CEO of Alder BioPharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on prevention of chronic migraines, from 2018 until 2019
- Executive Vice President and Chief Commercial Officer of Juno Therapeutics Inc., a biopharmaceutical company, from 2015 until 2018
- Held various senior roles at Amgen Inc., a multinational biopharmaceutical company, from 2000 until 2015
- Other current public company directorships:
- ADC Therapeutics SA, a commercial-stage oncology-focused biotechnology company, since 2023
- Autolus Therapeutics plc, a CAR T cell therapy company, since 2024
- Terns Pharmaceuticals, Inc., a biotechnology company, since February 2025
- Prior public company directorships within the last five years:
- Chinook Therapeutics Inc., a clinical-stage biopharmaceutical company, from 2023 until the company was acquired later in 2023
- Eliem Therapeutics, Inc., a biotechnology company, from 2020 until 2023
- Clovis Oncology Inc., a pharmaceutical company, from 2018 until 2022
- Immunomedics, a biotechnology company, from 2020 until the company was acquired later in 2020
Director Since 2024